Completed NA INTERVENTIONAL 2-arm NCT03265652

IPL and MGX Versus MGX Alone in the Treatment of Dry Eye Disease Secondary to MGD

Intense Pulsed Light and Meibomian Gland Expression (MGX) Versus MGX Alone in the Treatment of Dry Eye Disease Secondary to Meibomian Gland Dysfunction

Sponsor: Lumenis Be Ltd.

Conditions Dry Eye Meibomian Gland Dysfunction

Interventions Intense Pulsed Light (IPL) therapy Sham therapy

Updated 8 times since 2017 Last updated: Feb 19, 2020 Started: May 15, 2018 Primary completion: Apr 18, 2019 Completion: Apr 18, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03265652, this NA trial focuses on Dry Eye and Meibomian Gland Dysfunction and remains completed. Sponsored by Lumenis Be Ltd., it has been updated 8 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Nov 2022 — Jul 2024 [monthly]

Completed NA
Jan 2021 — Nov 2022 [monthly]

Completed NA
Mar 2020 — Jan 2021 [monthly]

Completed NA

Status: Unknown Status → Completed

▶ Show 3 earlier versions

Jan 2020 — Mar 2020 [monthly]

Unknown Status NA

Status: Not Yet Recruiting → Unknown Status
Jun 2018 — Jan 2020 [monthly]

Not Yet Recruiting NA
Sep 2017 — Jun 2018 [monthly]

Not Yet Recruiting NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Lumenis Be Ltd.

Data source: Lumenis Be Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Jerusalem, Israel